Pyxis Oncology ($PYXS) fell from $3.83 to as low as $1.90 on Tuesday, August 11, 2026. It got halted. It traded 12 times its normal volume. And the company put out no news at all: no press release, no SEC filing, nothing.
So what happened? The answer is buried in a financing deal from June 30. Here it is in plain English.
First, what the stock actually did
This part matters, because most people assume it drifted down all day. It did the opposite.
| Time (ET) | What happened |
|---|---|
| 9:30am to 12:22pm | Dead quiet. Stuck at $3.90 to $3.94. Prints of 100 shares at a time. |
| 12:22 to 12:27pm | Falls from $3.92 to $3.50 in under 5 minutes. |
| 12:27pm | Trading halted. Volatility halt, code LUDP. |
| 12:52pm | Reopens 25 minutes later at $2.63, on a single 969,524 share print. |
| Rest of day | Grinds to a $1.90 low, closes at $2.83. |
Two things stand out.
One: the stock was totally asleep for three hours, then fell 10% in five minutes. That is one big seller showing up, not a slow drift.
Two: a normal volatility halt lasts 5 minutes. This one lasted 25. That happens when the reopening auction cannot find enough buyers to clear. The sell order was simply bigger than the book. PYXS trades about 1 million shares on an average day. The reopening print alone was 970,000.
The setup: a deal from June 30
On June 30, Pyxis raised money in a private placement. The terms, straight from the SEC filing:
- 19,600,153 shares at $2.551 each, about $50 million
- 19,600,153 warrants (the right to buy more shares later) at $3.289 each
That second part is the whole story.
A warrant is a coupon to buy stock at a fixed price. If the stock is below $3.289, the coupon is worthless. If the stock is above $3.289, the coupon is worth real money.
There are 19.6 million of these coupons. That is about 24% more shares than currently exist. All of them sitting at $3.289.
The part that makes this unusual
Most warrants can be used any time. These cannot. From the filing:
The Common Warrants will be exercisable on or after the earlier of (i) the date on which the Company first publicly discloses clinical data from its micvotabart pelidotin (MICVO) Phase 1 monotherapy study ... or (ii) October 1, 2026
Read that again. The warrants unlock the moment the company releases its drug data.
So the big event everyone is waiting for is also the event that releases 19.6 million new shares onto the market. The good news and the dilution arrive at the same second.
The investors are allowed to bet against the stock
This is standard language in these deals, but most people never read it. From the purchase agreement:
... future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or "derivative" transactions, before or after the closing ... may negatively impact the market price of the Company's publicly-traded securities
... such hedging activities (if any) could reduce the value of the existing stockholders' equity interests in the Company. The Company acknowledges that such aforementioned hedging activities do not constitute a breach
The agreement even talks about them lining up shares to borrow so they can short in the future. There is no lock-up. Nothing stops these investors from selling or shorting.
To be clear: this is legal, normal, and disclosed. It is how small biotech financing works. But it means the people holding those 19.6 million coupons have both the reason and the written permission to sell stock when the price goes above $3.289.
Did they actually do it?
Short interest is public data, published twice a month. Here is $PYXS:
The deal closed July 2. Short interest jumped 963,855 shares, up 42%, in the very first reporting period after it closed. That is not a theory. That is FINRA data.
So why did the stock run up first?
Because the bank that sold the deal published a bullish note on it.
Wells Fargo Securities was the placement agent for the June 30 financing. That is in the filing. Then in early August, Wells Fargo research initiated coverage of PYXS with an Overweight rating and a $12 price target.
The stock went from $2.65 to $3.83 in six sessions, up 44%.
Again, this is normal and legal. Banks routinely start coverage after a deal once the quiet period ends. But the practical result was that the stock got pushed 21.6% above the $3.289 warrant strike for the first time since the deal.
| Date | Close |
|---|---|
| Jul 31 | $2.65 |
| Aug 3 | $3.04 |
| Aug 4 | $3.16 |
| Aug 5 | $3.13 |
| Aug 6 | $3.75 (first close above $3.289) |
| Aug 7 | $3.73 |
| Aug 10 | $3.83 |
| Aug 11 | hit $4.00, then crashed to $1.90 |
What was it not?
It was not the sector. In the exact same minutes, other head-and-neck-cancer and antibody-drug-conjugate stocks did nothing:
| Ticker | Range during the collapse |
|---|---|
| $BCAX (Bicara) | $24.09 to $25.11 |
| $SMMT (Summit) | $14.89 to $15.26 |
| $ADCT (ADC Therapeutics) | $1.13 to $1.14 |
| $ZNTL (Zentalis) | $4.09 to $4.14 |
All flat. This was specific to $PYXS.
It was not news. Pyxis has filed nothing with the SEC since July 10. Their investor relations news page stops at June 30. There was no press release on August 10 or August 11.
The bottom line
A stock that trades 1 million shares a day got hit by a seller who needed far more than that, on a day with no news, right after a bank-sponsored rally pushed it 21.6% above the strike price of 19.6 million warrants.
The people holding those warrants have a documented reason to sell stock at these levels, written permission to short, and no lock-up. Short interest already jumped 42% the moment the deal closed.
And where did it close? $2.50. The deal price was $2.551. It round-tripped right back to where those investors bought in.
What is still unknown?
Nobody knows who sold. No filing names a seller, and none exists yet. What we have is the structure, the incentive, the permission, and the timing.
Two things to watch:
- A Form 4 by Thursday, August 13. One holder, GordonMD, owns 12.1% of the company. Because they are above 10%, they legally must report any sale within two business days. If they sold Tuesday, it shows up Thursday.
- Quarterly fund filings on August 14. These will show who bought into the deal and whether the big funds that had been cutting came back. Millennium went from 3.54M shares to 398K, Citadel from 337K to 61K, Point72 from 188K to 32K.
Also worth knowing: the warrants unlock automatically on October 1 if the data has not come out by then, and the resale registration for the deal shares is due October 2. Everything opens in the same window.
References
SEC filings (company CIK 0001782223)
- Form 8-K, July 2, 2026, the private placement
- Exhibit 10.1, Securities Purchase Agreement, the short sale and hedging language
- Exhibit 4.1, Form of Common Warrant, the strike and unlock trigger
- Schedule 13G, BVF group, July 10, 2026
- Schedule 13G/A, GordonMD, July 2, 2026
- Schedule 13G/A Amendment No. 2, BVF, February 14, 2024, prior full exit
Company announcements
- Pyxis Oncology announces up to $114 million private placement, June 30, 2026
- Preliminary Phase 1 MICVO data, December 18, 2025
- Pyxis Oncology investor relations
Analyst coverage
Market data
Short interest from FINRA and Nasdaq semi-monthly reports, settlement dates June 30 and July 15, 2026. Intraday price, volume and halt records from The Desperate Trader platform data. Halt record: PYXS trading halted at 12:27 PM ET to downside (-8.62% daily), code LUDP, resumed 12:52 PM ET.